BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/2/2026 6:21:43 AM | Browse: 4 | Download: 2
 |
Received |
|
2025-12-22 08:09 |
|
Peer-Review Started |
|
2025-12-22 08:09 |
|
First Decision by Editorial Office Director |
|
2026-01-07 06:06 |
|
Return for Revision |
|
2026-01-07 06:06 |
|
Revised |
|
2026-01-12 18:53 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-28 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-28 13:33 |
|
Articles in Press |
|
2026-01-28 13:33 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-30 08:28 |
|
Publish the Manuscript Online |
|
2026-09-02 06:21 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Opinion Review |
| Article Title |
Alemtuzumab or basiliximab: Rethinking induction choice beyond acute rejection in kidney transplantation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Pranjal Kashiv, Khushboo Saxena, Manish Ramesh Balwani, Amit Pasari and Vivek B Kute |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Vivek B Kute, Professor, Department of Nephrology, Institute of Kidney Diseases and Research Center, Dr HL Trivedi Institute of Transplantation Sciences, Civil Hospital Campus, Ahmedabad 380016, Gujarat, India. drvivekkute@rediffmail.com |
| Key Words |
Kidney transplantation; Induction immunosuppression; Alemtuzumab; Basiliximab; Long-term graft outcomes |
| Core Tip |
Induction immunosuppression has traditionally been judged by its ability to prevent early acute rejection, yet long-term graft outcomes are increasingly shaped by factors beyond rejection alone. Contemporary evidence suggests that profound early immune depletion may confer delayed biological costs related to immune reconstitution, viral susceptibility, malignancy, and progressive graft dysfunction. The propensity-matched analysis discussed in this editorial highlight that Alemtuzumab and Basiliximab achieve comparable rejection control, while diverging meaningfully in long-term outcomes. These findings underscore the need to move beyond rejection-centred metrics and adopt a proportional, individualised approach to induction selection focused on durable graft preservation and patient safety. |
| Publish Date |
2026-09-02 06:21 |
| Citation |
Kashiv P, Saxena K, Balwani MR, Pasari A, Kute VB. Alemtuzumab or basiliximab: Rethinking induction choice beyond acute rejection in kidney transplantation. World J Transplant 2026; 16(3): 118000
|
| URL |
https://www.wjgnet.com/2220-3230/full/v16/i3/118000.htm |
| DOI |
https://doi.org/10.5500/wjt.118000 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
